Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
  • A01N37/06—Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/225—Polycarboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
  • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present invention relates to a semiochemical composition
• a semiochemical composition comprising methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities and mixtures thereof.
• Felidae are known to be solitary predators and they generally do not live in socially structural groups, with the exception of lions. Cats travel alone, hunt alone and only associate with other adult cats for mating. Domestic cats tend to be solitary and do not form large complex social groups. Cats are also very territorial by nature and mark their territory using scent derived from facial glands, feces, urine and anal glands. This territorial marking helps the cat to communicate with other cats and to minimize direct conflict. If another cat encroaches its marked territory an aggressive interaction is maintained by the cat to chase the invading cat off its territory by staring, hissing and growling and if this does not happen to work, through a short noisy violent physical attack.
• Cats do not invest energy in maintaining social bonds nor do they reconciliate after a conflict (Van den Bos (1998) Post-conflict stress-response in confined group- living cats (Felis sylvetris catus). Applied Animal Behaviour Science 59:323-330.
• Cats are not aggressive for any reason. There are in fact causes for the aggressiveness, as well as different type of aggression such as intercat aggression caused when two or more cats have a hostile relationship with each other; redirected aggression caused when the cat hears or sees something that it cannot have access to; petting-induced aggression caused by petting beyond the cats tolerance; fear aggression caused when the cat feels backed in a corner with no way out; play-related aggression caused while the cats plays; territorial aggression caused when another animal invades the cats territory; pain-induced aggression caused when one touches a hurting or injured spot on the cat; maternal aggression caused when a cat's kitten is threatened; and unprovoked aggression caused for no reason whatsoever.
• Semiochemicals are chemicals emitted by a plant or an animal that evokes a behavioral or physiological response in another organism. When the semiochemical affects an individual of the same species, it is called a pheromone. When the
• allelochemical a substance released by the body of particular species that cause a predictable reaction by another individual of the same species, which may serve, for example, as a specific attractant, social communicator, sexual stimulant, appeasement and effects basic animal behavior.
• pheromones such as aggregation pheromones that function in defense against predators, mate selection and overcoming host resistance by massive attack; alarm pheromones, which are released when attacked by a predator; epideictic pheromones, which are recognized by insects for signaling other insect that they should clutch elsewhere; releaser pheromones, which are attractant pheromones that some organisms use to attract mates from a distant of two miles or more; signal pheromones, which cause short term changes such as releasing a neurotransmitter which activates a response; primer pheromones, which trigger a change of developmental events; territorial pheromones, which mark the boundary of an animal's territory; trail pheromones, prevalent in insects, such as ants that lay down pheromones as they return to their nest with food; information pheromones, which are indicative of an animal's identity or territory; sex pheromones
• U.S. Patent 5,709,863 discloses a composition comprising an emulsion comprising a mixture of oleic acid, azaleic acid, pimelic acid, and palmitic acid, said mixture capable of preventing cats from urinating in a marked spot; and a compound of vegetal origin that has an attractive effect on cats. It does not describe a semiochemical to reduce social conflicts in cats and/or to improve social facilitation in multi-cat households or catteries or in kennels boarding multiple cats.
• Yet another object of the present invention is to provide a method to reduce social conflicts in multi-cat households or catteries or kennels that board cats.
• In yet another object is to provide a method to induce social facilitation of cats in multi-cat households or catteries or kennels that board cats.
• the present invention provides a semiochemical composition
• a semiochemical composition comprising methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities.
• a semiochemical composition comprising a mixture of methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities is also encompassed by the present invention.
• a semiochemical composition comprising between about 1 % to 8% (w%/w%) methyl laurate, between about 1 % to 8% (w%/w%) methyl myristate, between about 10% to 18% (w%/w%) methyl palmitate, between about 3% to 10% (w%/w%) methyl linoleate, between about 40% to 55% (w%/w%) methyl oleate, between about 1 % to 8% (w%/w%) methyl stearate, between about 5% to 15%
• a semiochemical composition comprising a mixture of between about 1 % to 8% (w%/w%) methyl laurate, between about 1 % to 8% (w%/w%) methyl myristate, between about 10% to 18% (w%/w%) methyl palmitate, between about 3% to 10% (w%/w%) methyl linoleate, between about 40% to 55% (w%/w%) methyl oleate, between about 1 % to 8% (w%/w%) methyl stearate, between about 5% to 15%
• a semiochemical composition comprising between about 2% to 6% (w%/w%) methyl laurate, between about 2% to 6% (w%/w%) methyl myristate, between about 1 1 % to 15% (w%/w%) methyl palmitate, between about 4% to 8% (w%/w%) methyl linoleate, between about 42% to 50% (w%/w%) methyl oleate, between about 2% to 6% (w%/w%) methyl stearate, between about 7% to 13% (w%/w%) dimethyl pimelate, between about 6% to 1 1 % (w%/w%) dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities is yet another embodiment of the invention.
• a semiochemical composition comprising a mixture of between about 2% to 6% (w%/w%) methyl laurate, between about 2% to 6% (w%/w%) methyl myristate, between about 1 1 % to 15% (w%/w%) methyl palmitate, between about 4% to 8% (w%/w%) methyl linoleate, between about 42% to 50% (w%/w%) methyl oleate, between about 2% to 6% (w%/w%) methyl stearate, between about 7% to 13% (w%/w%) dimethyl pimelate, between about 6% to 1 1 % (w%/w%) dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities is yet another embodiment of the invention.
• the semiochemical compositions, as described herein, further comprise an acceptable vehicle.
• This acceptable vehicle is a pharmaceutically acceptable vehicle or a veterinarian acceptable vehicle.
• the semiochemical compositions can further comprise a nontoxic filler or an enhancer composition.
• the nontoxic filler is selected from the group of fatty acids, alcohols, amines, squalene, glycerol and mixtures thereof, while the enhancer composition contains amines and fatty acids from indolic derivatives, esters of these amines and fatty acids, ketones, acetone, alcohols or sterols.
• the semiochemical compositions are an ester, an alcohol, a ketone, an amide, an ether, an aldehyde or a sterol derivative of methyl laurate, methyl oleate, methyl myristate, methyl palmitate, methyl linolate, methyl linoleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities and mixtures thereof.
• a solution comprising the semiochemical composition, as described herein, and a solvent is yet another aspect of the invention.
• the solution is in the form of a spray, an aerosol, is administered in diffuser, is microencapsulated or is a slow release matrix.
• a method to reduce social conflicts in multi-cat households or in catteries or kennels said method comprising releasing said semiochemical composition, as described herein, or the solution, as described herein, in an environment surrounding cats is another aspect of the invention.
• the semiochemical composition or said solution is released slowly. This release occurs between 3 to 5 weeks or 4 to 6 weeks and is generally in an indoor environment or an enclosed environment.
• the present invention provides a method for inducing social facilitation in cats said method comprising releasing said semiochemical compositions, as described herein, or the solution, as described herein, in an environment surrounding cats.
• the semiochemical composition or said solution is released slowly. This release occurs between 3 to 5 or 4 to 6 weeks and is generally in an indoor environment or an enclosed environment.
• a semiochemical composition, as described herein, for use in reducing social conflicts in catteries or kennels containing cats or in multi-cat households is another aspect of the invention.
• a semiochemical composition, as described herein, for use in inducing social facilitation in cats is yet another aspect of the present invention.
• Fig. 1 is a copy of the analogical visual scales that were filled out by the multi-cat owners and submitted at day 0, day 10, day 20 and day 30, which were presented in the analysis in the examples.
• Fig. 2 is a graph showing the final results from the aggressiveness analysis from the study over 30 days.
• the scale 0 means that the cats never stop fighting when they are together since they threaten, scratch and bite one another.
• Fig. 3 is a graph showing the final results from the affiliation analysis from the study over 30 days.
• the scale 0 means that the cat's owners were not confident to let their cats together in the same room.
• the scale 10 means that the cat's owners were confident to let their cats together in the same room.
• Fig, 4 is a graph showing the final results at day 20 and day 30 for the treated group and the placebo group.
• cat encompasses any member of the family Felidae including the common domestic cats as well as feral cats, tigers, lions, leopards, mountain lions, lynx, bobcats, cheetahs, ocelots and the like.
• semiochemical means a chemical emitted by a plant or an animal that evokes a behavioral or physiological response in another organism.
• a pheromone When the semiochemical affects an individual of the same species, it is called an allelochemical.
• social facilitation is meant that cats that live together in a household are familiar, affiliated and friendly with one another and share a group scent.
• stress-associated disease any disease whose symptoms increase due to stress.
• structural analogues is meant any compound that has a structure similar to that of another but differs in one or more functional groups, atoms, or substructures which are replaced with other functional groups, atoms, or substructures. For instance, replacement of methyl groups with heteroatoms in the methyl fatty acids, described herein.
• “Derivatives” as used herein include esters, alcohols, ketones, amides, ethers, aldehydes and sterols of the methyl esters of the fatty acids of methyl laurate, methyl myristate, methyl palmitate, methyl linolate, methyl linoleate, methyl stearate, methyl oleate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof and mixtures of methyl esters of the fatty acids of palmitate, linoleate, oleate, stearate, laurate, myristate, as well as structural analogs thereof and/or salts thereof.
• These methylated fatty acid derivatives can replace one or more of the fatty acids in the composition, as described herein, and have the same effects.
• “Isomers” includes structural isomerism and spatial isomerism and refers to the methyl esters of the fatty acids of palmitate, linoleate, oleate, stearate, laurate, myristate, dimethyl pimelate, dimethyl azelate as well as salts thereof, derivatives thereof and/or structural analogs that maintain the pheromonal appeasement activity and/or social facilitation activity thereof and mixtures of methyl esters of the fatty acids of palmitate, linoleate, oleate, stearate, laureate, myristate, as well as structural analogs thereof that maintain the semiochemical activity and/or social facilitation activity, salts thereof and/or derivatives thereof.
• mixtures encompasses the methyl esters of the fatty acids of palmitate, linoleate, oleate, stearate, laurate, myristate, dimethyl pimelate, dimethyl azelate as well as salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain the semiochemical activity and/or social facilitation activity in which the methyl esters of the fatty acids, as described herein, can be replaced with their salts and/or derivatives and/or isomers and/or structural analogs thereof that maintain the semiochemical activity and/or social facilitation activity.
• the mixture can comprise the methyl ester of palmitate and the methyl ester of linoleate, derivatives of oleate and stearate, isomers of methyl laurate dimethyl pimelate and dimethyl azelate and a structural analogue of myristate .
• solution is meant a solid or oil that is dispersed in a liquid either by being dissolved or in suspension.
• releasing means to deliver the semiochemical composition, as described herein, or the solution, as described herein.
• environment surroundings cats any surroundings in which the cats are present including houses, apartments, rooms, cages, enclosed porches and the like.
• Released slowly means that the semiochemical composition, as described herein, or the solution, as described herein, is released over a period of time and not at once.
• the time period may vary from 3 to 5 weeks or 4 to 6 weeks.
• acceptable vehicle any pharmaceutically acceptable vehicle or veterinary vehicle that does not interfere with the activity of the cat appeasing pheromone composition and is not toxic to the cats to which it is administered. It includes solvents, dispersion media, absorption delaying agents and the like. These pharmaceutically acceptable vehicles are described in Remington's Pharmaceutical Sciences 21 st edition 2005.
• An acceptable vehicle can be, for example, glycol ethers. It can be added to the cat appeasing pheromone during formulation.
• an active semiochemical composition or analogues thereof that is species-specific in cats and which can be used to enhance or act synergistically with the basic semiochemical composition, as described herein, salts and/or analogues thereof to increase the effectiveness in felines of the basic
• compositions contain all of the methyl ester fatty acids, salts thereof, derivatives thereof and isomers thereof and/or structural analogues, as described herein, as well as other additives that do not affect the semiochemical nature of the compositions.
• the present invention relates to the identification and synthesis of cat semiochemicals that are used to reduce social conflicts or induce social facilitation in cats.
• These compositions are made up of volatile molecules, the essential components being fatty acid methyl esters comprising methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogues thereof that maintain their semiochemical capabilities.
• a semiochemical composition comprising between about 1 % to 8% (w%/w%) methyl laurate, between about 1 % to 8% (w%/w%) methyl myristate, between about 10% to 18% (w%/w%) methyl palmitate, between about 3% to 10% (w%/w%) methyl linoleate, between about 40% to 55% (w%/w%) methyl oleate, between about 1 % to 8% (w%/w%) methyl stearate, between about 5% to 15%
• a semiochemical composition comprising between about 2% to 6% (w%/w%) methyl laurate, between about 2% to 6% (w%/w%) methyl myristate, between about 1 1 % to 15% (w%/w%) methyl palmitate, between about 4% to 8% (w%/w%) methyl linoleate, between about 42% to 50% (w%/w%) methyl oleate, between about 2% to 6% (w%/w%) methyl stearate, between about 7% to 13% (w%/w%) dimethyl pimelate, between about 6% to 1 1 % (w%/w%) dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities is yet another embodiment of the invention.
• the concentration of the semiochemical composition in the final product can range from about 0.1 % (w%/w%) to about 10%(w%/w%). In another aspect the concentration of the semiochemical composition in the final product can range from about 0.3% (w%/w%) to about 4%(w%/w%). %). In another aspect the concentration of the semiochemical composition in the final product can range from about 0.4%
• the semiochemical compositions of the present invention comprises a mixture of methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts, derivatives and isomers as well as their structural analogues, which represents between 65% to 95% (wt%/wt%) of the total composition, the remaining ingredients being nontoxic filler compounds such as fatty acids, alcohols, amines, squalene and glycerol; more particularly, aproic acid, azelaic acid, propanoic acid, geraniol, octadecatrianol, hexacosanol, trimethyl amine and methyl amine.
• An enhancer composition comprising between 5% to 35% (w%/w%) can also be added to the semiochemical composition, if desired.
• This enhancer composition comprises volatile organic compounds and mixtures thereof.
• This enhancer may be species-species specific in nature.
• the compounds that can be used in the enhancer composition include, but are not limited to amines and fatty acids from indolic derivatives, esters of these amines and fatty acids, ketones such as acetone, alcohols, sterols and the like.
• the cat appeasing semiochemical composition can be attached to a chemical carrier provided that the bioactive structure of the fatty acid methyl esters is preserved.
• carrier molecules include crown compounds, liposomes and carrier proteins.
• the pharmaceutically acceptable salts of the cat semiochemical compositions that are used in the compositions, described herein, include those that are organic or inorganic salts of the fatty acid esters of methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, methyl laurate, methyl myristate, dimethyl pimelate and dimethyl azelate. These are well known and described in the Physician's Desk Reference, The Merck Index and Goodman and Gilman's The Pharmacological Basis of Therapeutics.
• the pharmaceutically acceptable salts are, for example, sodium, potassium, ammonium, calcium and magnesium and salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and the like or salts formed with organic acids such as oxalic acid, fumaric acid, tartaric acid, malonic acid, acetic acid, citric acid, benzoic acid and the like.
• inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and the like
• organic acids such as oxalic acid, fumaric acid, tartaric acid, malonic acid, acetic acid, citric acid, benzoic acid and the like.
• the semiochemical compositions can also comprise an acceptable vehicle.
• This acceptable vehicle can be a pharmaceutically acceptable vehicle or a veterinarian acceptable vehicle.
• the pharmaceutically acceptable vehicle can be any acceptable carrier or vehicle that does not interfere with the pharmaceutical or veterinary activity of the composition and is not toxic to cats to it is administered. It includes solvents, dispersion media, coatings, absorption delaying agents and the like. These pharmaceutically acceptable vehicles are described in Remington's Pharmaceutical Sciences 22 nd edition 2012.
• An acceptable vehicle can be, for example, saline, buffered saline and the like. It can be added to the composition after its formulation.
• the semiochemical compositions as described herein, is an ester, an alcohol, a ketone, an amide, an ether, an aldehyde or a sterol derivative of
• a solution comprising the semiochemical composition, as described herein, and a solvent is yet another aspect of the invention.
• Solvents such as propylene glycol, alcohol, ether, chloroform, ethanol benzene, carbon disulfide, propyl alcohol, isopropanol, 2-propanol, fixed and volatile oils, diethylene glycol monoethyl ether, diethylene glycol monomethyl ether, diethylene glycol monopropyl ether, diethylene glycol monoisopropyl ether, diethylene glycol monobutyl ether, diethylene glycol monophenyl ether, diethylene glycol monobenzyl ether, diethylene glycol dimethyl ether,ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monopropyl ether, ethylene glycol monoisopropyl ether, ethylene glycol monobutyl ether, ethylene glycol monophenyl ether, ethylene glycol monobenzyl ether or ethylene glycol di
• the solution is in the form of a spray, an aerosol, is administered in a diffuser, is microencapsulated or is a slow release matrix or a spray. It can also be in the form of a cat collar which releases the semiochemical at a slow rate.
• a method to reduce social conflicts in multi-cat households by releasing said semiochemical composition, as described herein, or the solution containing the semiochemical composition, as described herein, is encompassed by the present invention.
• the multi-cat households have at least two cats.
• the semiochemical composition, as described herein, or said solution, as described herein, is released slowly into the environment surrounding cats. This slow release occurs between 4 to 6 weeks. In another aspect the slow release occurs between 3 to 5 weeks.
• the environment is an indoor environment or an enclosed environment.
• enclosed environments include pet carriers, enclosed rooms, animal pens and enclosed porches.
• a method to reduce social conflicts in catteries or kennels containing cats comprising releasing said semiochemical composition, as described herein or the solution containing the semiochemical composition, as described herein, in an environment surrounding cats.
• the semiochemical composition, as described herein, or said solution, as described herein is released slowly into the environment surrounding cats. This slow release occurs between 4 to 6 weeks. In another aspect the slow release occurs between 4 to 6 weeks or 3 to 5 weeks.
• the environment is an indoor environment or an enclosed environment.
• enclosed environments include pet carriers, enclosed rooms, animal pens and enclosed porches.
• the present invention provides a method for inducing social facilitation in cats said method comprising releasing said semiochemical compositions, as described herein, or the solution containing the semiochemical composition, as described herein, in an environment surrounding cats.
• the semiochemical composition or said solution is released slowly. This slow release occurs between 4 to 6 weeks. In another aspect the slow release occurs between 3 to 5 weeks.
• the semiochemical compositions, as described herein, for use in reducing social conflicts in catteries or kennels containing cats is yet another aspect of the present invention.
• the semiochemical compositions, as described herein, for use in inducing social facilitation in cats is another embodiment of the present invention.
• the semiochemical compositions and solutions, as described herein contain fatty acids.
• Fatty acids are commercially available from various companies in solid form. However, since it is difficult to solubilize fatty acids, the fatty acid is generally added to the solvent under constant agitation and at a temperature of between about 37°C to about 38°C more preferably about 38°C.
• compositions of the present invention can be tested for the efficacy to manage social conflicts in cats and/or to induce social facilitation in cats.
• the present semiochemical compositions were discovered after intense evaluation of the behavior of cats with different pheromones.
• Example 1 Evaulation of the Efficacy of Treatment with semiochemical vs. placebo This example was to test for the aggressiveness of multi-cat households in which the cats were currently in a situation of conflict.
• the evaluation of the treatment which consisted of a mixture of 1 1.4% (wt%/wt%) of dimethyl pimelate, 7.8% (wt%/wt%) of dimethyl azelate.
• the two analogical visual scales(AVS) were for aggressiveness(AVS 1 ) and affiliation (AVS 2).
• the cats' owner filled out these two forms at day 0 (TO), day 10 (T1 ), day 20 (T2) and day 30 (T3)of the study.
• the control was evaluated at 60 days (T4) by telephone.
• T1 , T2 and T3 were effectuated by telephone with the people conducting this study.
• the questioner containing the analogical visual scales (AVS) used in the experiment and given to the owners of multi-cat households are described in Figure 1.
• the diffusers were labeled 1 and 2 and were given to the cat owners depending on the surface area of the home.
• Table 1 shows the distribution of the diffusers and their content:
• the ratio of F variances and the p variances are set forth in Table 3 below based on the data from the student T test for Group A and Group B.
• the two analogical visual scales(AVS) were for aggressiveness(AVS 1 ) and affiliation (AVS 2).
• AVS 2 3.49 2.35 3.51 4.30 2.60 3.10 28.0 -0.6343 0.525 Day 0
• the ratio of F variances and the p variances are set forth in Table 21 below based on the data from the student T test for Group A and Group B in Table 20.
• the semiochemical that was tested in this example was a mixture of 4.5%
• Example 2 The same testing was performed on 16 cases of aggressive cat housemates from seven different veterinary clinics as in Example 1. This aggressive behavior was studied with households having 2 or 3 cats that were aggressive among themselves, but not aggressive towards their owner. Furthermore, their aggression did not entail wounding the other cats and the cats were not on any other treatments.
• T0,T1 ,T2,T3 evaluation was by telephone.
• the AVS1 and AVS2 was evaluated in the same manner as in Example 1 using the same form filled out by the owner of the cats.
• Example 1 The same testing was performed on cases of aggressive cat housemates as in Example 1. This aggressive behavior was studied with households having 2 or 3 cats that were aggressive among themselves, but not aggressive towards their owner.
• the semiochemical that is tested in this example was a mixture of 15.5%
• the treatment improved social facilitation and eased aggressiveness in multi-cat households.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Wood Science & Technology (AREA)
• Biomedical Technology (AREA)
• Zoology (AREA)
• Dentistry (AREA)
• Plant Pathology (AREA)
• Pest Control & Pesticides (AREA)
• Anesthesiology (AREA)
• Environmental Sciences (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Agronomy & Crop Science (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Fodder In General (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (2)

Family

ID=53499035

Family Applications (1)

Country Status (20)

Cited By (1)

Families Citing this family (8)

Citations (4)

Family Cites Families (3)

• 2015
  • 2015-03-17 HU HUE15733524A patent/HUE049993T2/hu unknown
  • 2015-03-17 SM SM20200341T patent/SMT202000341T1/it unknown
  • 2015-03-17 MX MX2016012111A patent/MX390644B/es unknown
  • 2015-03-17 CA CA2943085A patent/CA2943085C/en active Active
  • 2015-03-17 LT LTEP15733524.1T patent/LT3119198T/lt unknown
  • 2015-03-17 PT PT157335241T patent/PT3119198T/pt unknown
  • 2015-03-17 RU RU2016137669A patent/RU2671176C2/ru active
  • 2015-03-17 WO PCT/IB2015/000633 patent/WO2015140637A2/en not_active Ceased
  • 2015-03-17 JP JP2017500455A patent/JP6814728B2/ja active Active
  • 2015-03-17 EP EP15733524.1A patent/EP3119198B1/en active Active
  • 2015-03-17 AU AU2015233073A patent/AU2015233073B2/en active Active
  • 2015-03-17 PE PE2016001645A patent/PE20170072A1/es unknown
  • 2015-03-17 PL PL15733524T patent/PL3119198T3/pl unknown
  • 2015-03-17 ES ES15733524T patent/ES2803076T3/es active Active
  • 2015-03-17 CN CN201580022207.1A patent/CN106456591B/zh active Active
  • 2015-03-17 NZ NZ724712A patent/NZ724712A/en unknown
  • 2015-03-17 DK DK15733524.1T patent/DK3119198T3/da active
  • 2015-03-17 US US15/127,060 patent/US10258593B2/en active Active
  • 2015-03-17 BR BR112016021468-4A patent/BR112016021468B1/pt active IP Right Grant
• 2016
  • 2016-09-20 CL CL2016002362A patent/CL2016002362A1/es unknown

Patent Citations (6)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events